Recro Pharma Restarting Trial For Post-Surgery Pain Drug
A clinical drug study by Malvern’s Recro Pharma is being refined to better differentiate the pharmaceutical, an intranasal form of dexmedetomidine called Dex-IN, from its placebo in a bid to achieve statistical significance.
“There remains a significant unmet medical need for opioid-sparing analgesics, a need which we continue to believe may be addressed with Dex-IN,” Recro President and CEO Gerri Henwood said in a StreetInsider.com report.
Dex-IN is being developed to treat acute pain after bunionectomy surgery, and a key change to the clinical study is administering the drug a day after surgery rather than the day of. The article noted that no serious adverse events have occurred in the trial.
Read more about the progress of Recro Pharma’s Dex-IN trial and its plan to change the study on StreetInsider.com here.
________
Top photo credit: Greg McMullin via photopin cc
Connect With Your Community
Subscribe to stay informed!
"*" indicates required fields